Phase III GiACTA study shows Roche ’s Actemra/RoActemra is superior to steroids alone in maintaining steroid-free remission for people with giant cell arteritis

Roche today announced positive results from the phase III GiACTA study, which evaluated Actemra ®/RoActemra® (tocilizumab) in people with giant cell arteritis (GCA).
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news